Wire · opportunities
Samchundang tempers FDA hope as Korea weighs disclosure rules and GMP woes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 July 2026 · Fusion42 review
South Korean generic drug maker Samchundang claims FDA pre-ANDA feedback clears the path for approval of its oral semaglutide generic using only bioequivalence studies, but experts and the FDA's own guidelines suggest the response is directional guidance, not formal approval. The company faces credibility questions given past disclosure controversies and has refused to publicly share the FDA's full response.
This Wire brief sits within Fusion42's coverage of Digital Health, and 1 source has reported it between 20 Jul 2026 and 26 Jul 2026.
◆ ◆ The Wire takeaway
If you're building a generic drug and the FDA gives you directional feedback in pre-ANDA, you don't have approval yet—but Samchundang's overstatement shows how easy it is to mislead investors and patients about where you actually stand. The FDA won't say yes until it reviews your full submission.
◆ Coverage
1 source · first reported 20 Jul 2026 · latest 26 Jul 2026
◆ Related on Wire
◆ Topics